Expand ARTL Menu
ARTL MENU

ARTL Latest Press Releases

-- July 22, 2026 --

New Analysis of Over 50 Studies Showed that All the Non-Prescription CBD Products Researched Fell Short of Therapeutic Efficacy - Reinforcing the Case for Artelo's Optimized ART12.11 CBD Composition Globe Newswire 8:39 AM

-- July 16, 2026 --

Artelo Biosciences Announces Results from a Nonclinical Osteoarthritis Study Supporting ART26.12 as a Potential First-in-Class New Therapy for Chronic Pain Conditions Globe Newswire 8:48 AM

-- July 14, 2026 --

Artelo Biosciences Issues Reminder to Shareholders to Vote in Advance of Annual Meeting on July 17, 2026 Globe Newswire 8:47 AM

-- July 13, 2026 --

Artelo Biosciences Announces Positive Results with ART27.13 in a Nonclinical Model of Paclitaxel-Induced Peripheral Neuropathy Globe Newswire 9:02 AM

-- July 1, 2026 --

Artelo Biosciences Announces New Data Supporting ART26.12 as a Potential First-in-Class Therapy for Chronic Pain associated with Spinal Cord Injury Globe Newswire 8:42 AM

-- June 30, 2026 --

Artelo Biosciences Presents Evidence for a Common Lipid-Signaling Link Across Multiple Potential Indications for Its FABP5 Inhibitor Platform at ICRS 2026 Globe Newswire 8:57 AM

-- June 29, 2026 --

Artelo Biosciences Presents Clinical and Biomarker Data Supportive of the Development of ART26.12 and Follow-On FABP5 Inhibitors at ICRS 2026 Globe Newswire 8:45 AM

-- June 10, 2026 --

Artelo Biosciences Presents ART26.12 Human Metabolite Data Demonstrating Favorable Drug Metabolism Characteristics Associated with Clinical Development Success Globe Newswire 7:38 AM

-- May 14, 2026 --

Artelo Biosciences Provides Business Update Outlining Upcoming Milestones and Reports 2026 First Quarter Financial Results Globe Newswire 4:05 PM

-- April 28, 2026 --

Artelo Biosciences Announces Strategic Collaboration with Artificial Intelligence (AI) Leader ScienceMachine Highlighting New Expansion Opportunities and Insights for FABP5 Inhibitor Development Globe Newswire 8:25 AM

-- April 20, 2026 --

Artelo Announces Peer-Reviewed Publication Supporting its FABP5 Inhibitor ART26.12 as a Novel Pain Treatment with a Potentially First-in-Class Profile Globe Newswire 7:50 AM

-- April 7, 2026 --

Artelo Biosciences Regains Compliance with Nasdaq Listing Requirements Globe Newswire 7:50 AM

-- March 30, 2026 --

Artelo Biosciences Announces Closing of $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules Globe Newswire 4:46 PM

-- March 27, 2026 --

Artelo Biosciences Announces $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules Globe Newswire 10:40 AM

-- March 25, 2026 --

Artelo Biosciences Expands ART27.13 Development as a Potential Companion Therapy to GLP-1 Treatments Globe Newswire 4:05 PM
Artelo Biosciences Expansion into $16.3B Glaucoma Market, Via Fully Funded Study, Highlights Multi-Platform Pipeline Strength Globe Newswire 7:31 AM

-- March 18, 2026 --

Biotech Breakthroughs and Strategic Pivots Fuel Market Momentum Globe Newswire 10:41 AM
Vanderbilt Report: Artelo Biosciences Expands Into $16.3 Billion Glaucoma Market With Fully Funded Clinical Study Globe Newswire 8:07 AM
Artelo Announces Third-Party Fully Funded Clinical Study Agreement to Evaluate ART27.13 in Glaucoma Patients Globe Newswire 7:41 AM

-- March 6, 2026 --

Artelo Biosciences Announces Reverse Stock Split Globe Newswire 8:00 AM
Market Data Delayed 15 Minutes